Department of Clinical Genetics, Leiden University Medical Centre, Leiden, the Netherlands.
Department of Clinical Genetics, UMC Groningen, the Netherlands.
Crit Rev Oncol Hematol. 2021 Jul;163:103338. doi: 10.1016/j.critrevonc.2021.103338. Epub 2021 May 25.
Lynch syndrome (LS) is a hereditary cancer syndrome that accounts for 3% of all new colorectal cancer (CRC) cases. Patients carry a germline pathogenic variant in one of the mismatch repair (MMR) genes (MLH1, MSH2, MSH6 or PMS2), which encode proteins involved in a post-replicative proofreading and editing mechanism. The clinical presentation of LS is highly heterogeneous, showing high variability in age at onset and penetrance of cancer, which may be partly attributable to the molecular profiles of carcinomas. This review discusses the frequency of alterations in the WNT/B-CATENIN, RAF/MEK/ERK and PI3K/PTEN/AKT pathways identified in all four LS subgroups and how these changes may relate to the 'three pathway model' of carcinogenesis, in which LS CRCs develop from MMR-proficient adenomas, MMR-deficient adenomas or directly from MMR-deficient crypts. Understanding the specific differences in carcinogenesis for each LS subgroup will aid in the further optimization of guidelines for diagnosis, surveillance and treatment.
林奇综合征(LS)是一种遗传性癌症综合征,占所有新发结直肠癌(CRC)病例的 3%。患者携带一种错配修复(MMR)基因(MLH1、MSH2、MSH6 或 PMS2)中的种系致病性变异,这些基因编码参与复制后校对和编辑机制的蛋白质。LS 的临床表现高度异质,发病年龄和癌症的外显率差异很大,这可能部分归因于癌的分子谱。这篇综述讨论了在所有四个 LS 亚组中鉴定出的 WNT/B-连环蛋白、RAF/MEK/ERK 和 PI3K/PTEN/AKT 通路改变的频率,以及这些改变如何与“三种途径模型”相关联,即 LS CRC 从 MMR 功能正常的腺瘤、MMR 缺陷型腺瘤或直接从 MMR 缺陷型隐窝发展而来。了解每个 LS 亚组中致癌作用的具体差异将有助于进一步优化诊断、监测和治疗的指南。